Form 8-K - Current report:
SEC Accession No. 0000950170-25-096656
Filing Date
2025-07-17
Accepted
2025-07-17 17:12:40
Documents
10
Period of Report
2025-07-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20250715.htm   iXBRL 8-K 60917
  Complete submission text file 0000950170-25-096656.txt   169187

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20250715.xsd EX-101.SCH 26365
12 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20250715_htm.xml XML 4708
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 251131481
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)